Canara HSBC Life Insurance Company Limited (CANHLIFE) Stock Forecast & Price Target
CANHLIFE Analyst Ratings
There are no analyst ratings in the last 3 months.
CANHLIFE Stock 12 Month Forecast
There are no analyst price targets in the last 3 months.
Detailed List of Analyst Forecasts
| Analyst Profile | Expert Firm | Price Target | Position | Upside / Downside | Action | Date | Follow | Article |
|---|---|---|---|---|---|---|---|---|
 Unknown AnalystNot Ranked | Motilal Oswal | INR 180 | buy | 48.45%Upside | Reiterated | 01/13/26 |
| Analyst Profile | Date | Price Target | Position | Upside / Downside | Action | Follow | Article | Expert Firm |
|---|---|---|---|---|---|---|---|---|
| Unknown AnalystNot Ranked | 01/13/26 | INR 180 | buy | 48.45%Upside | Reiterated | Motilal Oswal |
CANHLIFE Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 0 | 0 | 0 | 0 | 0 |
In the current month, CANHLIFE has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CANHLIFE average Analyst price target in the past 3 months is ―.
CANHLIFE Financial Forecast
CANHLIFE Earnings Forecast
Next quarter’s earnings estimate for CANHLIFE is INR 0.45 with a range of ― to ―. The previous quarter’s EPS was INR 0.45. CANHLIFE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year CANHLIFE has Performed in-line its overall industry.
CANHLIFE Sales Forecast
Next quarter’s sales forecast for CANHLIFE is INR 25.60B with a range of ― to ―. The previous quarter’s sales results were INR 25.60B. CANHLIFE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year CANHLIFE has Performed in-line its overall industry.